Evidence map›Paper›PMID 32066466›Full record

ArticleJournal of neuroinflammation2020

Zerumbone ameliorates behavioral impairments and neuropathology in transgenic APP/PS1 mice by suppressing MAPK signaling.

Lei Li, Xiang-Hui Wu, Xiao-Jing Zhao, Lu Xu, Cai-Long Pan, Zhi-Yuan Zhang

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Neurotrophic Natural Products.Progress in the chemistry of organic natural products · 2024
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Lei LiDepartment of Pathology, Nanjing Medical University, Longmian Avenue 101, Nanjing, 211166, China.
Xiang-Hui WuDepartment of Pathology, Nanjing Medical University, Longmian Avenue 101, Nanjing, 211166, China.
Xiao-Jing ZhaoDepartment of Pathology, Nanjing Medical University, Longmian Avenue 101, Nanjing, 211166, China.
Lu XuDepartment of Pathology, Nanjing Medical University, Longmian Avenue 101, Nanjing, 211166, China.
Cai-Long PanDepartment of Pathology, Nanjing Medical University, Longmian Avenue 101, Nanjing, 211166, China.
Zhi-Yuan ZhangDepartment of Pathology, Nanjing Medical University, Longmian Avenue 101, Nanjing, 211166, China. zzy@njmu.edu.cn.
Nanjing Medical University · CN

Funding

National Natural Science Foundation of China 81571240National Natural Science Foundation of China 81771171
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a major clinical problem, but there is a distinct lack of effective therapeutic drugs for this disease. We investigated the potential therapeutic effects of zerumbone, a subtropical ginger sesquiterpene, in transgenic APP/PS1 mice, rodent models of AD which exhibit cerebral amyloidosis and neuroinflammation.

methodsThe N9 microglial cell line and primary microglial cells were cultured to investigate the effects of zerumbone on microglia. APP/PS1 mice were treated with zerumbone, and non-cognitive and cognitive behavioral impairments were assessed and compared between the treatment and control groups. The animals were then sacrificed, and tissues were collected for further analysis. The potential therapeutic mechanism of zerumbone and the signaling pathways involved were also investigated by RT-PCR, western blot, nitric oxide detection, enzyme-linked immunosorbent assay, immunohistochemistry, immunofluorescence, and flow cytometry analysis.

resultsZerumbone suppressed the expression of pro-inflammatory cytokines and induced a switch in microglial phenotype from the classic inflammatory phenotype to the alternative anti-inflammatory phenotype by inhibiting the mitogen-activated protein kinase (MAPK)/nuclear factor-kappa B signaling pathway in vitro. After a treatment period of 20 days, zerumbone significantly ameliorated deficits in both non-cognitive and cognitive behaviors in transgenic APP/PS1 mice. Zerumbone significantly reduced β-amyloid deposition and attenuated pro-inflammatory microglial activation in the cortex and hippocampus. Interestingly, zerumbone significantly increased the proportion of anti-inflammatory microglia among all activated microglia, potentially contributing to reduced β-amyloid deposition by enhancing phagocytosis. Meanwhile, zerumbone also reduced the expression of key molecules of the MAPK pathway, such as p38 and extracellular signal-regulated kinase.

conclusionsOverall, zerumbone effectively ameliorated behavioral impairments, attenuated neuroinflammation, and reduced β-amyloid deposition in transgenic APP/PS1 mice. Zerumbone exhibited substantial anti-inflammatory activity in microglial cells and induced a phenotypic switch in microglia from the pro-inflammatory phenotype to the anti-inflammatory phenotype by inhibiting the MAPK signaling pathway, which may play an important role in its neuroprotective effects. Our results suggest that zerumbone is a potential therapeutic agent for human neuroinflammatory and neurodegenerative diseases, in particular AD.

Indexed as

Amyloid beta-Protein PrecursorPresenilin-1Alzheimer DiseaseAnimalsAnimals, NewbornCells, CulturedFemaleHumansMaleMAP Kinase Signaling SystemMaze LearningMiceMice, Inbred C57BLMice, TransgenicNesting BehaviorSesquiterpenesAmyloid beta-Protein PrecursorPresenilin-1SesquiterpeneszerumboneAlzheimer’s diseaseAPP/PS1 transgenic mouseCerebral amyloidosisMAPK signaling pathwayNeuroinflammationZerumbone

Identifiers

PMID32066466
PMCPMC7027354
OpenAlexW3009178956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.